The Dipeptidyl Peptidase-4 Inhibitor Saxagliptin as a Candidate Treatment for Disorders of Consciousness: A Deep Learning and Retrospective Clinical Analysis
Our findings suggest incretin-based medications in general, and saxagliptin in particular, as potential novel therapeutic agents for DOC. Further prospective clinical trials are needed to confirm their efficacy and safety in DOC.
Authors
- Jeffrey N. Chiang (ORCID: https://orcid.org/0000-0002-6843-1355)
- Caroline Schnakers (ORCID: https://orcid.org/0000-0003-1143-0658)
- Daniel Toker (ORCID: https://orcid.org/0000-0003-0983-8937)
- Martin M. Monti (ORCID: https://orcid.org/0000-0001-5511-3780)
- Paul Vespa (ORCID: https://orcid.org/0000-0003-0936-9501)
Institutions
- University of California, Los Angeles (US)
- Casa Colina Centers for Rehabilitation (US)
Publication Details
- Journal
- Neurocritical Care
- Published
- 2025-02-04
- DOI
- https://doi.org/10.1007/s12028-025-02217-0
- Citations
- 5
- Primary Topic
- Attention Deficit Hyperactivity Disorder
- Type
- article
- Field-Weighted Citation Impact
- 7.36